

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/03/31	2017/12/31	2017/03/31
Balance Sheet			
Current assets			
Cash and cash equivalents	370,282	342,061	210,339
Current financial assets at amortised cost	188,640	0	0
Current investments in debt instrument without active market	0	283,586	448,871
Accounts receivable, net	18,716	67,304	17,536
Accounts receivable due from related parties, net	99	1,533	289
Other receivables	3,201	1,262	5,313
Current tax assets	924	2,225	1,973
Current inventories	56,172	46,206	54,686
Prepayments	16,200	11,586	22,185
Other current assets	13,221	9,928	48,586
Total current assets	667,455	765,691	809,778
Non-current assets			
Non-current financial assets at fair value through other comprehensive income	115,790	0	0
Non-current financial assets at cost	0	87,000	20,000
Property, plant and equipment	356,178	363,827	351,545
Intangible assets	1,670	1,957	2,108
Deferred tax assets	63,376	56,696	39,027
Other non-current assets	37,095	37,628	86,400
Total non-current assets	574,109	547,108	499,080
Total assets	1,241,564	1,312,799	1,308,858
Current liabilities			
Current contract liabilities	6,898	0	0
Accounts payable	13,703	9,567	20,737
Other payables	72,538	114,951	29,603
Other payables to related parties	0	321	0
Other current liabilities	546	2,941	6,544
Total current liabilities	93,685	127,780	56,884
Non-current liabilities			
Other non-current liabilities	41,139	41,153	2,256
Total non-current liabilities	41,139	41,153	2,256
Total liabilities	134,824	168,933	59,140
Share capital			
Ordinary share	1,121,545	1,121,180	1,120,445
Advance receipts for share capital	0	604	814
Total share capital	1,121,545	1,121,784	1,121,259
Capital surplus			
Capital surplus, additional paid-in capital	266,733	266,494	621,871
Capital surplus, treasury share transactions	2,812	2,812	2,812
Capital surplus, employee share options	34,144	29,856	20,813
Total capital surplus	303,689	299,162	645,496
Retained earnings			
Unappropriated retained earnings (accumulated deficit)	-259,673	-189,469	-429,426
Total retained earnings	-259,673	-189,469	-429,426
Other equity interest			
Total other equity interest	28,790	0	0
Treasury shares	-87,611	-87,611	-87,611
Total equity	1,106,740	1,143,866	1,249,718
Total liabilities and equity	1,241,564	1,312,799	1,308,858
Number of share capital awaiting retirement	0	0	0
Equivalent issue shares of advance receipts for ordinary share	0	36,500	44,000
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000	2,200,000

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/01/01To2018/03/31	2017/01/01To2017/03/31
Income Statement		
Total operating revenue	17,447	25,234
Total operating costs	40,746	40,633
Gross profit (loss) from operations	-23,299	-15,399
Gross profit (loss) from operations	-23,299	-15,399
Operating expenses		
Selling expenses	2,355	1,947
Administrative expenses	8,847	11,023
Research and development expenses	34,848	40,106
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	875	0
Total operating expenses	46,925	53,076
Net operating income (loss)	-70,224	-68,475
Non-operating income and expenses		
Total other income	999	6,290
Other gains and losses, net	-7,585	-10,473
Finance costs, net	74	0
Total non-operating income and expenses	-6,660	-4,183
Profit (loss) from continuing operations before tax	-76,884	-72,658
Total tax expense (income)	-6,634	99
Profit (loss) from continuing operations	-70,250	-72,757
Profit (loss)	-70,250	-72,757
Other comprehensive income		
Components of other comprehensive income that will not be reclassified to profit or loss		
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-46	0
Total other comprehensive income	46	0
Total comprehensive income	-70,204	-72,757
Basic earnings per share		
Total basic earnings per share	-0.64	-0.66

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2018/01/01To2018/03/31	2017/01/01To2017/03/31
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-76,884	-72,658
Profit (loss) before tax	-76,884	-72,658
Depreciation expense	17,870	13,348
Amortization expense	287	234
Expected credit loss (gain) / Provision (reversal of provision) for bad debt expense	875	39
Interest expense	74	0
Interest income	-979	-1,278
Share-based payments	4,288	5,518
Loss (gain) on disposal of property, plan and equipment	0	-112
Impairment loss on non-financial assets	428	179
Total adjustments to reconcile profit (loss)	22,843	17,928
Decrease (increase) in accounts receivable	47,713	5,753
Decrease (increase) in accounts receivable due from related parties	1,434	24,183
Decrease (increase) in other receivable	-2,083	-2,389
Decrease (increase) in inventories	-10,394	-4,470
Decrease (increase) in prepayments	-4,614	-2,196
Decrease (increase) in other current assets	200	-184
Total changes in operating assets	32,256	20,697
Increase (decrease) in contract liabilities	5,015	0
Increase (decrease) in accounts payable	4,136	-1,332
Increase (decrease) in other payable	-43,152	-11,554
Increase (decrease) in other payable to related parties	-321	-6
Increase (decrease) in other current liabilities	-512	816
Increase (decrease) in net defined benefit liability	-14	-15
Total changes in operating liabilities	-34,848	-12,091
Total changes in operating assets and liabilities	-2,592	8,606
Total adjustments	20,251	26,534
Cash inflow (outflow) generated from operations	-56,633	-46,124
Income taxes refund (paid)	1,301	-66
Net cash flows from (used in) operating activities	-55,332	-46,190
Cash flows from (used in) investing activities		
Acquisition of financial assets at amortised cost	-40,000	0
Proceeds from disposal of financial assets at amortised cost	134,946	0
Acquisition of investments in debt instrument without active market	0	-32,639
Proceeds from disposal of investments in debt instrument without active market	0	69,167
Increase in prepayments for investments	0	-67,000
Acquisition of property, plant and equipment	-606	-10,926
Increase in refundable deposits	-80	0
Increase in other financial assets	-3,493	0
Increase in prepayments for business facilities	-8,337	-13,964
Interest received	1,123	1,306
Net cash flows from (used in) investing activities	83,553	-54,056
Cash flows from (used in) financing activities		
Exercise of employee share options	0	814
Net cash flows from (used in) financing activities	0	814
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	28,221	-99,432
Cash and cash equivalents at beginning of period	342,061	309,771
Cash and cash equivalents at end of period	370,282	210,339
Cash and cash equivalents reported in the statement of financial position	370,282	210,339
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

Provided by: Myonax Biotech Inc.
 Fiscal year: Yearly
 Unit: NTS thousand

2018/03/31 Statement of Stockholders' Equity

Accounting Title	Unit: NTS thousand														
	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealized gains (losses) on financial assets measured at fair value through other comprehensive income	Unrealized gains (losses) on available-for-sale financial assets	Gains (losses) on effective portion of cash flow hedges	Gains (losses) on effective portion of hedges of net investments in foreign operations	Equity related to non-current assets (or disposal groups) classified as held for sale	Others	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,121,180	604	1,121,784	289,162	-189,469	-189,469	0	0	0	0	0	0	0	-87,611	1,143,866
Effects of retrospective application and retrospective restatement	0	0	0	0	0	0	28,790	0	0	0	0	0	28,790	0	28,790
Equity at beginning of period after adjustments	1,121,180	604	1,121,784	289,162	-189,469	-189,469	28,790	0	0	0	0	0	28,790	-87,611	1,172,656
Profit (loss)	0	0	0	0	-70,250	-70,250	0	0	0	0	0	0	0	0	-70,250
Other comprehensive income	0	0	0	0	46	46	0	0	0	0	0	0	0	0	46
Total comprehensive income	0	0	0	0	-70,204	-70,204	0	0	0	0	0	0	0	0	-70,204
Share-based payments	365	-604	-239	4,527	0	0	0	0	0	0	0	0	0	0	4,288
Total increase (decrease) in equity	365	-604	-239	4,527	-70,204	-70,204	0	0	0	0	0	0	0	0	-65,916
Equity at end of period	1,121,545	0	1,121,545	303,689	-259,673	-259,673	28,790	0	0	0	0	0	28,790	-87,611	1,106,740

2017/03/31 Statement of Stockholders' Equity

Accounting Title	Unit: NTS thousand															
	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Exchange differences on translation of foreign financial statements	Unrealized gains (losses) on financial assets measured at fair value through other comprehensive income	Unrealized gains (losses) on available-for-sale financial assets	Gains (losses) on effective portion of cash flow hedges	Gains (losses) on effective portion of hedges of net investments in foreign operations	Equity related to non-current assets (or disposal groups) classified as held for sale	Others	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,120,065	807	1,120,872	639,611	-356,669	-356,669	0	0	0	0	0	0	0	0	-87,611	1,316,143
Equity at beginning of period after adjustments	1,120,065	807	1,120,872	639,611	-356,669	-356,669	0	0	0	0	0	0	0	0	-87,611	1,316,143
Profit (loss)	0	0	0	0	-72,757	-72,757	0	0	0	0	0	0	0	0	0	-72,757
Other comprehensive income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Total comprehensive income	0	0	0	0	-72,757	-72,757	0	0	0	0	0	0	0	0	0	-72,757
Share-based payments	440	7	447	5,885	0	0	0	0	0	0	0	0	0	0	0	-6,332
Total increase (decrease) in equity	440	7	447	5,885	-72,757	-72,757	0	0	0	0	0	0	0	0	0	-66,423
Equity at end of period	1,120,445	814	1,121,259	645,496	-429,426	-429,426	0	0	0	0	0	0	0	0	-87,611	1,249,719